Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Corporate Update (September 2018)

16 slides from Reata Pharmaceuticals's corporate update, Sep 25, 2018

  1. Slide 1: Management Call to Discuss Phase 2 PHOENIX Updates

    MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX UPDATES September 25, 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Bardoxolone is Currently in Development for Five Rare Forms of CKD

    Bardoxolone is Currently in Development for Five Rare Forms of CKD CARDINAL study in Alport syndrome Phase 2 portion demonstrated significant retained benefit at one year Pivotal Phase 3 portion is ongoing with data expected in 2H19 PHOENIX study designed to determine efficacy of bardoxolone (Bard)

  4. Slide 4: Trial Design

    PHOENIX Trial Design Phase 2, open-label, multi-center, US-only trial Four separate cohorts of patients with ADPKD, IgAN, T1D CKD, and FSGS Targeting enrollment of 25 to 30 patients per cohort Primary endpoint is increase in eGFR from baseline at Week 12 Enrolling large range of eGFR (30-90 mL/min1)

  5. Slide 5: IgA Nephropathy Overview

    IgA Nephropathy Overview Most prevalent primary chronic glomerular disease worldwide Annual incidence of 1 case per 100,000 persons and affects roughly 120,000 patients in US Deposition of immunoglobulin complexes in the glomerulus causes inflammation, fibrosis and progressive loss of kidney functio

  6. Slide 6: IgAN: Baseline Characteristics and Historical eGFR Decline Data

    PHOENIX IgAN: Baseline Characteristics and Historical eGFR Decline Data PHOENIX IgAN cohort enrolled 26 patients Average eGFR upon study entry 46 mL/min despite 96% of patients receiving standard of care ACEi/ARB Historical eGFR data from 3 years prior to enrollment collected for 23/26 patients Aver

  7. Slide 7: IgAN: Bard Significantly Improved eGFR

    PHOENIX IgAN: Bard Significantly Improved eGFR Bard produced statistically significant increase in eGFR of 8.0 mL/min at Week 12 Increase represents recovery of ~ six prior years of loss based on historical data BL eGFR Change from Baseline in eGFR (n=26) WK4 WK12 Mean ± SE 46.2 ± 2.5 6.8 ± 1.0 8.0

  8. Slide 8: IgAN: Urinary Protein Unchanged

    PHOENIX IgAN: Urinary Protein Unchanged Patients optimized on available therapies upon study entry as evidenced by low urinary protein within international treatment guideline goals (<1,000 mg/g)1 Bard treatment resulted in no significant change in urinary albumin excretion UACR Over Time A1: Normal

  9. Slide 9: Overview of CKD Associated with Type 1 Diabetes

    Overview of CKD Associated with Type 1 Diabetes Type 1 diabetes (T1D) affects an estimated 1.25 million patients in the US CKD affects approximately 10-20% of patients with T1D or roughly 160,000 patients in the US Average annual decline of 1.4 mL/min In patients with T1D CKD, hyperglycemia due to p

  10. Slide 10: T1D: Baseline Characteristics and Historical eGFR Decline Data

    PHOENIX T1D: Baseline Characteristics and Historical eGFR Decline Data PHOENIX T1D CKD cohort enrolled 28 patients Historical eGFR data from 3 years prior to enrollment collected for 22/28 patients Average annual loss of eGFR of 1.9 mL/min prior to study entry Patients had lost ~ one-third of their

  11. Slide 11: T1D: Bard Significantly Improved eGFR in T1D Patients

    PHOENIX T1D: Bard Significantly Improved eGFR in T1D Patients Bard produced statistically significant increase in eGFR of 5.5 mL/min at Week 12 Increase represents recovery of ~ three prior years of loss based on historical data Lower treatment effect and higher variability in subset of patients wit

  12. Slide 12: T1D: Urinary Protein Unchanged in T1D Patients

    PHOENIX T1D: Urinary Protein Unchanged in T1D Patients Patients had normal to near-normal levels of urinary protein at baseline Bard treatment did not change urinary albumin excretion despite the increase in eGFR UACR Over Time A1: Normal (<30) UACR Categories A2: Microalbuminuria (30-300) A3: Macro

  13. Slide 13: Patient Disposition and Summary of Safety

    Patient Disposition and Summary of Safety Bard was well-tolerated 23/26 (88%) IgAN patients completed treatment 24/28 (86%) T1D patients completed treatment No treatment-related serious adverse events in IgAN or T1D patients AE profile similar to other CKD populations that have been studied AEs were

  14. Slide 14: Bard Improved eGFR Across Multiple Types of CKD

    Bard Improved eGFR Across Multiple Types of CKD Increases in eGFR observed in six distinct patient populations Long-term eGFR increases of one to two years observed in three patient populations eGFR improvement post-withdrawal observed in two patient populations Acute changes in eGFR correlate with

  15. Slide 15: Bard in CKD: Recent Highlights and Key Upcoming Milestones

    Bard in CKD: Recent Highlights and Key Upcoming Milestones CARDINAL trial in Alport syndrome Released one year Phase 2 data Phase 3 portion of CARDINAL underway Next milestone: One year, pivotal Phase 3 data in 2H19 PHOENIX trial in rare forms of CKD Released complete ADPKD, IgAN, and T1D CKD data N

  16. Slide 16: Q&A

    Q&A

Reata Pharmaceuticals — Corporate Update (September 2018) on 6ix